W.A.F. (Erik) Marijt. MD PhD


  • Hematologist


Dr. Erik W.A. Marijt studied Medicine at the Leiden University. After graduation in 1987 he started his PhD research in the Laboratory for Experimental Hematology of the department Hematology, LUMC. The title of his thesis was “The role of minor histocompatibility antigens in bone marrow graft rejection“ (1993). From 1993 until 1998 he received his training in Internal Medicine at the “Ziekenhuis Leyenburg “, The Hague and the Leiden University Medical Center. From 1998 until 2002 he received his training in Hematology at the Department Hematology of the Leiden University Medical Center. During that period he also worked on a project  entitled “Immunotherapy for relapsed leukemia after allogeneic stem cell transplantation using in vitro cultured donor-derived leukemia-reactive T lymphocytes; an early clinical study “. The study was performed in the “GMP-facility of the Laboratory of Experimental Hematology. In 2002 he was appointed staff member at the Department of Hematology and became Head of the Central Laboratory of Clinical Hematology and the Interdivisional Flowcytometry Core Facility.

Clinical interests

Allogeneic stem cell transplantation as treatment for malignant and non-malignant hematological diseases; treatment of T cell Non Hodgkin lymphomas and chronic lymphocytic leukemia; autologous stem cell transplantation as treatment for systemic slerosis.

Research interests

His research focuses on two subjects:

  • Identification of mechanisms that determine functional immunological reconstitution after T cell depleted allogeneic stem cell transplantation. This line of research tries to define the prerequisites, such as sufficient number of functional T- and B lymphocytes, for successful vaccination against infectious agents and against antigens expressed on normal and malignant residual recipient-derived hematopoietic cells.
  • Hematopoietic lineage specific chimerism analysis to identify critical recipient cell populations required for the induction of allogeneic immune responses after donor lymphocyte infusion to cure patients with malignant and non-malignant hematological diseases. This involves detailed analysis of changes in mixed chimerism in various hematopoietic lineages after donor lymphocyte infusion. These changes are subsequently correlated with disappearance of malignant cells using malignancy-specific molecular markers.

Selected publications

  • Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning. Hoogendoorn M, Jedema I, Barge RM, van Luxemburg-Heijs SA, Beaumont F, Marijt WAF, Willemze R, Falkenburg JH. Leukemia. 2007 Dec;21(12):2569-74.
  • Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation. Marijt WAF, Wafelman A, van der Hoorn M, van Bergen C, Bongaerts R, van Luxemburg-Heijs S, van den Muijsenberg J, Wolbers JO, van der Werff N, Willemze R, Falkenburg JH. Haematologica. 2007 Jan;92(1):72-80.
  • Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath “in the bag” as T-cell depletion: the Leiden experience. Barge RM, Starrenburg CW, Falkenburg JH, Fibbe WE, Marijt WAF, Willemze R. Bone Marrow Transplant. 2006 Jun;37(12):1129-34.
  • Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Posthuma EF, Marijt WAF, Barge RM, van Soest RA, Baas IO, Starrenburg CW, van Zelderen-Bhola SL, Fibbe WE, Smit WM, Willemze R, Falkenburg JH. Biol Blood Marrow Transplant. 2004 Mar;10(3):204-12.
  • Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Marijt WAF, Heemskerk MH, Kloosterboer FM, Goulmy E, Kester MG, van der Hoorn MA, van Luxemburg-Heys SA, Hoogeboom M, Mutis T, Drijfhout JW, van Rood JJ, Willemze R, Falkenburg JH. Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2742-7.


Leids Universitair Medisch Centrum
Gebouw 1
Kamer C-02-142

Albinusdreef 2
2333 ZA Leiden
Tel: +31 71 526 1249

Postzone C2-R
Postbus 9600
2300 RC Leiden

E-mail: w.a.f.marijt@lumc.nl